Le Lézard
Classified in: Health
Subject: MAT

Vireo Health Announces Inclusion in Horizons Marijuana Index ETFs


MINNEAPOLIS, June 27, 2019 /PRNewswire/ -- Vireo Health International, Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), a leading science-focused, multi-state cannabis company, today announced that its shares have been included in the Horizons US Marijuana Index ETF (HMUS) and the Horizons Emerging Marijuana Growers Index ETF (HMJR).

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

The Horizons US Marijuana Index (HMUS) was the first of its kind and seeks to track the price movements of a portfolio of North American publicly listed companies with significant business activities in the United States marijuana or hemp industries. Stocks must meet certain requirements to be included in this ETF. A company must be listed on an US or Canadian exchange, represent significant exposure in the hemp and marijuana industries, have a market capitalization greater than CAD$75M, a stock price greater than CAD$0.25, and have a 30 day average daily trading volume of greater than CAD$100,000. Stocks in this ETF are rebalanced quarterly so that no single stock holds more than 10.0 percent of the weight in the index.

The Horizons Emerging Marijuana Growers Index (HMJR) is designed to provide exposure to the performance of a basket of primarily North American publicly listed small-capitalization companies primarily involved in the cultivation, production and/or distribution of marijuana. Stocks must meet certain requirements to be included in this ETF. A company must be listed on a regulated stock exchange in a developed market; be a cultivator, producer, and/or distributor of marijuana or cannabis; and have a market capitalization greater than CAD$50M. Stocks in this ETF are rebalanced quarterly so that no single stock holds more than eight percent of the weight in the index.

About Vireo Health International, Inc.
Vireo Health International, Inc.'s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry. Vireo's physician-led team of more than 350 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company is currently licensed in eleven states and territories: Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania, Puerto Rico and Rhode Island. For more information about the company, please visit www.vireohealth.com.

Contact Information            

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
[email protected]
(612) 314-8995

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
[email protected]   
(267) 221-4800

SOURCE Vireo Health International, Inc.


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: